Buy Recommendation for EyePoint Pharmaceuticals: Strong Clinical Positioning and Market Potential of Duravyu in Wet AMD
I'm PortAI, I can summarize articles.
JonesTrading's Debanjana Chatterjee maintains a Buy rating on EyePoint Pharmaceuticals with a $43 target, citing strong clinical positioning of its wet AMD candidate, Duravyu. The company is conducting two Phase 3 trials, LUGANO and LUCIA, aligning with FDA guidance for potential expedited approval. Duravyu aims to address unmet needs in the wet AMD market, offering a durable solution compared to current treatments. Mizuho Securities also reiterated a Buy rating with a $33 target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments